Please login to the form below

Not currently logged in

Neurodegenerative research needs better cooperation, say GlobalData

And public funding must be provided to eradicate business risks

Alzheimer's disease brain scanAdvancements in drug discovery for neurodegenerative diseases could be boosted by greater cooperation between pharma companies and small research programmes, says GlobalData.

Kyle S Nicholson, GlobalData's analyst covering neurology, claims evolving ideas are constantly needed in the field that covers Parkinson's and Alzheimer's disease.

Nicholson commented: “Big pharmaceutical corporations essentially depend on research at smaller levels to drive their business and expand their portfolios, but they must find a more sustainable strategy for scouting and funding early-stage research to identify better biomarkers.

“By expanding their teams that evaluate the potential of smaller research programs, beginning early investment in their activities and encouraging investigation into new ideas, the best targets will have a better chance at quickly advancing into clinical trials.”

Nicholson also stated that although it is essential that larger and smaller players within the pharma industry collaborate to facilitate progress in Alzheimer's and Parkinson's drug development, public funding must be provided to reduce the risks involved from a business perspective.

He added: “One of the most problematic areas in the AD drug development process is phase II, where the level of research is associated with a needed investment of up to $25 million, and the success rate is as low as 25%.

“Alleviating development costs will subtract from the list of investors' worries, and the tax benefits must also be significant for companies willing to invest in projects at an early stage, as this will provide the funding needed to accelerate research and clear regulatory hurdles.”

In recent weeks, pharma has proved its dedication to research for Alzheimer's with the announcement of the $100m global Dementia Discovery Fund and an additional $2m donation to further the Biomarkers Across Neurodegenerative Diseases (BAND) programme.

Article by
Kirstie Pickering

23rd March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...